Seattle Genetics reports Fourth Quarter and Year 2013 Financial Results

12-02-2014 Business Wire HealthComments (0)


Seattle Genetics (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2013. The company also highlighted Adcetris (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming milestones. “Our 2013 financial results highlight our progress with Adcetris, which now has approvals or marketing authorizations i

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top